LOS ANGELES, CA--(Marketwired - Sep 24, 2013) - MyMedicalRecords, Inc., a wholly owned subsidiary of MMRGlobal, Inc. (OTCQB: MMRF) (collectively, "MMR"), today announced the filing of a complaint for patent infringement against Allscripts Healthcare Solutions, Inc. The complaint states that Allscripts provides health information services to consumers and healthcare providers and is infringing on MMR's Personal Health Records (PHR) patents including U.S. Patent No. 8,301,466, entitled "Method and System for Providing Online Records," and U.S. Patent No. 8,498,883, entitled "Method for Providing a User with a Service for Accessing and Collecting Prescriptions." According to the complaint, Allscripts acquired all or substantially all the assets of Jardogs, LLC in or about March 2013. As a result of the transaction, Allscripts provides products and services under the FollowMyHealth™ Universal Health Record, described by Jardogs as the "next generation of patient portals, combining patient-provider communication with a patient managed personal health record." The complaint, filed in the United States District Court for the Central District of California, case number CV13-7052-SBW, on September 23, 2013, seeks monetary damages as well as a permanent injunction and is available on the court's website http://www.pacer.gov/.

MMR believes that Allscripts infringes on its patents through the sale of FollowMyHealth along with other health information services for consumers and healthcare providers, including but not limited to, other Allscripts patient portals, The complaint alleges that Allscripts has directly infringed and continues to infringe, the '466 Patent and the '883 Patent by making, using, offering for sale, and/or selling in the United States certain methods or systems disclosed and claimed in the '466 and '883 Patents, including, but not limited to, the FollowMyHealth product. The complaint alleges that, for example, Allscripts FollowMyHealth product implements a method for providing a user with the ability to access and collect Personal Health Records associated with the user in a secure and private manner, according to one or more claims of the '466 Patent; and implements a method for providing a user with an ability to access, collect, and/or manage drug prescriptions associated with the user in a secure and private manner, according to one or more claims of the '883 Patent.

In addition to the Company's primary business of providing secure online Personal Health Records under its patented MyMedicalRecords brand, as well as its MMRPro document imaging and management systems for healthcare professionals, MMR is also actively involved in licensing and protecting its global health information technology portfolio. This includes eight U.S. patents with hundreds of claims focused on the digital transmission of medical records, including Personal Health Records. The most recent U.S. patent, covering prescriptions, was received on June 30, 2013. MMR also has additional U.S. patent applications pending which include numerous continuation applications. Internationally, MMR has received issued patents and has pending applications in countries of commercial interest such as Australia, Canada, Singapore, New Zealand, Mexico, Hong Kong, China, Japan, South Korea, Israel, and European nations.

According to Robert H. Lorsch, MMRGlobal CEO, "This complaint is in addition to the one MMR announced on May 20th against what remains of Jardogs, which is still pending. While MMR's business is primarily selling our Personal Health Record products and services, we remain focused on the monetization of our patents and other intellectual property both domestically and internationally. To accomplish our goals, we are continually meeting with EMR vendors, large hospital groups, retail pharmacies, laboratory systems, EHR and PHR vendors, and other healthcare professionals in our efforts to sell MMR's products and services and monetize our patents and other intellectual property."

MMR's PHR is built on proprietary, patented technologies that facilitate, among other things, documents, images and voicemail messages to be transmitted and stored using a variety of methods, including fax, e-mail, phone, or file upload, creating an integrated telecommunications platform that does not rely on any specific EMR system to populate a user's account. Further, in the event of an emergency or disaster, medical personnel and first responders can retrieve potentially lifesaving information via a separate emergency login to the patient's PHR.

The complaint also alleges that Allscripts, while infringing on MMR's patents, has also induced and continues to induce others including distributors, agents, resellers and users to directly infringe one or more claims of both the '466 and '883 Patents.

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.

Forward-Looking Statements
 All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both MMR's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR's filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information:


Michael Selsman
Public Communications Co.
(310) 922-7033